v3.26.1
Acquisition - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 08, 2026
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2026
Jun. 30, 2025
Business Combination [Line Items]          
Issuance of Class A common stock for settlement of contingent consideration       $ 8,703 $ 0
Developed technology          
Business Combination [Line Items]          
Remaining Useful Life in Years   5 years 9 months 18 days   5 years 9 months 18 days  
Scale BioScience Inc. Acquisition          
Business Combination [Line Items]          
Cash consideration     $ 10,000    
Issuance of Class A common stock for settlement of contingent consideration     8,700    
Milestone payment     30,000    
Cash payment to third party     $ 600    
Scale BioScience Inc. Acquisition | Common Class A          
Business Combination [Line Items]          
Equity consideration, number of share issued (in shares)     396,584    
Proteintech Genomics Inc          
Business Combination [Line Items]          
Percentage of outstanding shares acquired 100.00%        
Total adjusted price consideration $ 6,101        
Prepaid supply rights $ 12,400        
Prepaid supply rights, amortization period 10 years        
Business combination, acquisition-related cost, expense   $ 1,000      
Proteintech Genomics Inc | Developed technology          
Business Combination [Line Items]          
Remaining Useful Life in Years 10 years 10 years   10 years